Last year, a quiet J.P. Morgan Healthcare Conference meant few deals, few major updates. That set the tone for much of the year on the M&A front.

Big Pharma Pfizer will cut around 300 jobs and a number of earlier stage projects from its neuroscience pipeline.

Neurogastrx grabbed $45 million to bring its gastroparesis drug through proof of concept.

Ex-Receptos CEO Faheem Hasnain has been keeping a low profile since selling the company to Celgene, but now he is back at the helm of a new biotech.

The gene therapy sector has a new player—Generation Bio—which promises to provide safer, more controllable treatments that do away with the need to use viruses…

The round positions BioNTech to mount a multifront attack on cancer, spearheaded by mRNA therapies and supported by modalities including CAR-T cells.

French microbiome biotech Enterome has got off a €32 million ($38.5 million) series D round with the help of some big-name players.

The series A positions a team with résumés dotted with senior posts at Serono, Eli Lilly and Novartis to advance multifunctional anticancer drugs.

Boehringer Ingelheim is deepening its venture fund pockets from €100 million to €250 million as it looks to change up its investment strategy.